UK markets close in 5 minutes

Nyxoah S.A. (NYXH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
23.50+0.50 (+2.17%)
As of 9:50AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close23.00
Open22.90
Bid21.35 x 1000
Ask23.48 x 1000
Day's range22.90 - 23.51
52-week range21.00 - 37.00
Volume707
Avg. volume9,903
Market cap600.364M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.14
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est42.19
  • Globe Newswire

    Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients

    INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients Notified Body DEKRA approves IFU changes to remove warning regarding CCC patients Mont-Saint-Guibert, Belgium – October 4, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea

  • Globe Newswire

    Information on the total number of voting rights and shares

    REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), October 1, 2021, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of 27,000 new shares on September 30, 2021 pursuant to the exercise of subscription rights. Share capital: EUR 4,388,714.69 Total number of securiti

  • Globe Newswire

    Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

    INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse Mont-Saint-Guibert (Belgium), September 14, 2021, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that